Cargando…

The Role of Circulating Protein and Metabolite Biomarkers in the Development of Pancreatic Ductal Adenocarcinoma (PDAC): A Systematic Review and Meta-analysis

BACKGROUND: Pancreatic ductal adenocarcinoma (PDAC) has a poor prognosis, and this is attributed to it being diagnosed at an advanced stage. Understanding the pathways involved in initial development may improve early detection strategies. This systematic review assessed the association between circ...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kumar, Swati, Santos, Ralph J., McGuigan, Andrew J., Singh, Urvashi, Johnson, Peter, Kunzmann, Andrew T., Turkington, Richard C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Association for Cancer Research 2022
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9377754/ https://www.ncbi.nlm.nih.gov/pubmed/34810209 http://dx.doi.org/10.1158/1055-9965.EPI-21-0616

Ejemplares similares

Immune cell infiltrates as prognostic biomarkers in pancreatic ductal adenocarcinoma: a systematic review and meta‐analysis
por: McGuigan, Andrew J, et al.
Publicado: (2021)

Overexpression of Mesothelin in Pancreatic Ductal Adenocarcinoma (PDAC)
por: Le, Kai, et al.
Publicado: (2020)

The microbiome as a potential diagnostic biomarker for pancreatic ductal adenocarcinoma (PDAC)
por: Wheatley, Roseanna C., et al.
Publicado: (2022)

Modifiable Pancreatic Ductal Adenocarcinoma (PDAC) Risk Factors
por: Michalak, Natalia, et al.
Publicado: (2023)

Circulating Tumor Cell Subpopulations Predict Treatment Outcome in Pancreatic Ductal Adenocarcinoma (PDAC) Patients
por: Freed, Ian M., et al.
Publicado: (2023)

Simple Serum Pancreatic Ductal Adenocarcinoma (PDAC) Protein Biomarkers—Is There Anything in Sight?
por: Kapszewicz, Monika, et al.
Publicado: (2021)

Clinically impactful metabolic subtypes of pancreatic ductal adenocarcinoma (PDAC)
por: Pervin, Jannat, et al.
Publicado: (2023)

The role of survivin in the progression of pancreatic ductal adenocarcinoma (PDAC) and a novel survivin-targeted therapeutic for PDAC
por: Brown, Matthew, et al.
Publicado: (2020)

ANO1 (TMEM16A) in pancreatic ductal adenocarcinoma (PDAC)
por: Sauter, D. R. P., et al.
Publicado: (2014)

Systemic therapy in pancreatic ductal adenocarcinomas (PDACs)—basis and current status
por: Ramaswamy, Anant, et al.
Publicado: (2022)

Regulatory role of RNA modifications in the treatment of pancreatic ductal adenocarcinoma (PDAC)
por: Chen, Hao, et al.
Publicado: (2023)

SIRT 1 Overexpression is Associated with Metastasis of Pancreatic Ductal Adenocarcinoma (PDAC) and Promotes Migration and Growth of PDAC Cells
por: Li, Siqin, et al.
Publicado: (2016)

Upregulated MicroRNA-483-3p is an Early Event in Pancreatic Ductal Adenocarcinoma (PDAC) and as a Powerful Liquid Biopsy Biomarker in PDAC
por: Shao, Huilin, et al.
Publicado: (2021)

MicroRNAs as Indicators of Malignancy in Pancreatic Ductal Adenocarcinoma (PDAC) and Cystic Pancreatic Lesions
por: Prinz, Christian, et al.
Publicado: (2022)

The EPH/Ephrin System in Pancreatic Ductal Adenocarcinoma (PDAC): From Pathogenesis to Treatment
por: Papadakos, Stavros P., et al.
Publicado: (2023)

Pancreatic Ductal Adenocarcinoma (PDAC) circulating tumor cells influence myeloid cell differentiation to support their survival and immunoresistance in portal vein circulation
por: Arnoletti, Juan Pablo, et al.
Publicado: (2022)

Perineural Invasion in Pancreatic Ductal Adenocarcinoma (PDAC): A Saboteur of Curative Intended Therapies?
por: Felsenstein, Matthäus, et al.
Publicado: (2022)

Screening of potential pain genes in pancreatic ductal adenocarcinoma (PDAC) based on bioinformatics methods
por: Xu, Qian, et al.
Publicado: (2023)

MSP-RON Signaling Is Activated in the Transition From Pancreatic Intraepithelial Neoplasia (PanIN) to Pancreatic Ductal Adenocarcinoma (PDAC)
por: Li, Ce, et al.
Publicado: (2019)

Neurotensin is a Versatile Modulator of In Vitro Human Pancreatic Ductal Adenocarcinoma Cell (PDAC) Migration
por: Mijatovic, Tatjana, et al.
Publicado: (2007)

Neutrophil–lymphocyte ratio (NLR) was associated with prognosis and immunomodulatory in patients with pancreatic ductal adenocarcinoma (PDAC)
por: Xiang, Zi-jun, et al.
Publicado: (2020)

PDAC-ANN: an artificial neural network to predict pancreatic ductal adenocarcinoma based on gene expression
por: Almeida, Palloma Porto, et al.
Publicado: (2020)

WDR79 promotes aerobic glycolysis of pancreatic ductal adenocarcinoma (PDAC) by the suppression of SIRT4
por: Yin, Wenke, et al.
Publicado: (2023)

CA 19-9 but Not IGF-1/IGFBP-2 Is a Useful Biomarker for Pancreatic Ductal Adenocarcinoma (PDAC) and Chronic Pancreatitis (CP) Differentiation
por: Wlodarczyk, Barbara, et al.
Publicado: (2023)

Molecular, morphological and survival analysis of 177 resected pancreatic ductal adenocarcinomas (PDACs): Identification of prognostic subtypes
por: Schlitter, Anna Melissa, et al.
Publicado: (2017)

NAB-paclitaxel and gemcitabine in metastatic pancreatic ductal adenocarcinoma (PDAC): from clinical trials to clinical practice
por: De Vita, Ferdinando, et al.
Publicado: (2016)

Gene Expression Characteristics of Tumor and Adjacent Non-Tumor Tissues of Pancreatic Ductal Adenocarcinoma (PDAC) In-Silico
por: Güven, Emine
Publicado: (2022)

Circulating Nucleic Acids as Novel Biomarkers for Pancreatic Ductal Adenocarcinoma
por: McGowan, Ryan, et al.
Publicado: (2022)

Longitudinal Study of Circulating Biomarkers in Patients with Resectable Pancreatic Ductal Adenocarcinoma
por: Dopico, Pablo J., et al.
Publicado: (2022)

MicroRNA profiling of pancreatic ductal adenocarcinoma (PDAC) reveals signature expression related to lymph node metastasis
por: Lemberger, Moran, et al.
Publicado: (2019)

Pancreatic Ductal Adenocarcinoma (PDAC) Organoids: The Shining Light at the End of the Tunnel for Drug Response Prediction and Personalized Medicine
por: Frappart, Pierre-Olivier, et al.
Publicado: (2020)

In Silico analyses of host immunity and stroma provide prognostic factors in early stage pancreatic ductal adenocarcinoma (PDAC)
por: Williams, Madison H., et al.
Publicado: (2020)

Expression of Chosen Carcinoembryonic-Related Cell Adhesion Molecules in Pancreatic Intraepithelial Neoplasia (PanIN) Associated with Chronic Pancreatitis and Pancreatic Ductal Adenocarcinoma (PDAC)
por: Zińczuk, Justyna, et al.
Publicado: (2019)

Open-source curation of a pancreatic ductal adenocarcinoma gene expression analysis platform (pdacR) supports a two-subtype model
por: Torre-Healy, Luke A., et al.
Publicado: (2023)

A novel prognostic factor TIPE2 inhibits cell proliferation and promotes apoptosis in pancreatic ductal adenocarcinoma (PDAC)
por: Sun, Yuqi, et al.
Publicado: (2021)

Circulating Monocytes Serve as Novel Prognostic Biomarker in Pancreatic Ductal Adenocarcinoma Patients
por: Hansen, Frederik J., et al.
Publicado: (2023)

Cyclin Dependent Kinase-1 (CDK-1) Inhibition as a Novel Therapeutic Strategy against Pancreatic Ductal Adenocarcinoma (PDAC)
por: Wijnen, Rosa, et al.
Publicado: (2021)

Potential Metabolite Biomarkers for Early Detection of Stage-I Pancreatic Ductal Adenocarcinoma
por: Cao, Yingying, et al.
Publicado: (2022)

Predictive Modeling for Voxel-Based Quantification of Imaging-Based Subtypes of Pancreatic Ductal Adenocarcinoma (PDAC): A Multi-Institutional Study
por: Zaid, Mohamed, et al.
Publicado: (2020)

Serum Metabolite Biomarkers for Pancreatic Tumors: Neuroendocrine and Pancreatic Ductal Adenocarcinomas—A Preliminary Study
por: Skubisz, Karolina, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_q5qrv0m62l1i59m04d721g4e9c